268 related articles for article (PubMed ID: 15200426)
41. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
42. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
[TBL] [Abstract][Full Text] [Related]
43. L-tetrahydropalmatine attenuates cisplatin-induced nephrotoxicity via selective inhibition of organic cation transporter 2 without impairing its antitumor efficacy.
Li C; Li L; Yi Y; Wang W; Yuan J; Tan F; Fang D; Zeng S; Zhou H; Jiang H
Biochem Pharmacol; 2020 Jul; 177():114021. PubMed ID: 32389634
[TBL] [Abstract][Full Text] [Related]
44. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.
Stöhr W; Paulides M; Bielack S; Jürgens H; Koscielniak E; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Feb; 48(2):140-7. PubMed ID: 16724313
[TBL] [Abstract][Full Text] [Related]
45. Cisplatin nephrotoxicity: in vitro studies with precision-cut rabbit renal cortical slices.
Phelps JS; Gandolfi AJ; Brendel K; Dorr RT
Toxicol Appl Pharmacol; 1987 Sep; 90(3):501-12. PubMed ID: 3310337
[TBL] [Abstract][Full Text] [Related]
46. Platinum-induced kidney damage: Unraveling the DNA damage response (DDR) of renal tubular epithelial and glomerular endothelial cells following platinum injury.
Krüger K; Thomale J; Stojanović N; Osmak M; Henninger C; Bormann S; Fritz G
Biochim Biophys Acta; 2015 Mar; 1853(3):685-98. PubMed ID: 25565603
[TBL] [Abstract][Full Text] [Related]
47. Modulating the Activity of the Human Organic Cation Transporter 2 Emerges as a Potential Strategy to Mitigate Unwanted Toxicities Associated with Cisplatin Chemotherapy.
Hucke A; Kantauskaite M; Köpp TN; Wehe CA; Karst U; Nedvetsky PI; Ciarimboli G
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474165
[TBL] [Abstract][Full Text] [Related]
48. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
Negoro K; Yamano Y; Nakashima D; Saito K; Nakatani K; Shiiba M; Bukawa H; Yokoe H; Uzawa K; Wada T; Tanzawa H; Fujita S
Oncol Rep; 2009 Feb; 21(2):443-9. PubMed ID: 19148521
[TBL] [Abstract][Full Text] [Related]
49. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
50. Comparisons of segment-specific toxicity of platinum-based agents and cadmium using S1, S2, and S3 cells derived from mouse kidney proximal tubules.
Fujishiro H; Taguchi H; Hamao S; Sumi D; Himeno S
Toxicol In Vitro; 2021 Sep; 75():105179. PubMed ID: 33905841
[TBL] [Abstract][Full Text] [Related]
51. In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands.
Momekov G; Ferdinandov D; Bakalova A; Zaharieva M; Konstantinov S; Karaivanova M
Arch Toxicol; 2006 Sep; 80(9):555-60. PubMed ID: 16485120
[TBL] [Abstract][Full Text] [Related]
52. TCEP-based rSDS-PAGE AND nLC-ESI-LTQ-MS/MS for oxaliplatin metalloproteomic analysis.
Mena ML; Moreno-Gordaliza E; Gómez-Gómez MM
Talanta; 2013 Nov; 116():581-92. PubMed ID: 24148449
[TBL] [Abstract][Full Text] [Related]
53. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration.
Esteban-Fernández D; Verdaguer JM; Ramírez-Camacho R; Palacios MA; Gómez-Gómez MM
J Anal Toxicol; 2008 Mar; 32(2):140-6. PubMed ID: 18334097
[TBL] [Abstract][Full Text] [Related]
54. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
55. Unidirectional transport from apical to basolateral compartment of cobalt ion in polarized Madin-Darby canine kidney cells.
Nagao M; Sugaru E; Kambe T; Sasaki R
Biochem Biophys Res Commun; 1999 Apr; 257(2):289-94. PubMed ID: 10198205
[TBL] [Abstract][Full Text] [Related]
56. Comparative analysis of cell injury after exposure to antitumor platinum derivatives in kidney tubular epithelial cells.
Kitada N; Takara K; Itoh C; Minegaki T; Tsujimoto M; Sakaeda T; Yokoyama T
Chemotherapy; 2008; 54(3):217-23. PubMed ID: 18560229
[TBL] [Abstract][Full Text] [Related]
57. The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity.
Daley-Yates PT; McBrien DC
Biochem Pharmacol; 1985 May; 34(9):1423-8. PubMed ID: 4039567
[TBL] [Abstract][Full Text] [Related]
58. Klotho has dual protective effects on cisplatin-induced acute kidney injury.
Panesso MC; Shi M; Cho HJ; Paek J; Ye J; Moe OW; Hu MC
Kidney Int; 2014 Apr; 85(4):855-70. PubMed ID: 24304882
[TBL] [Abstract][Full Text] [Related]
59. Differential toxicity of cisplatin, carboplatin, and CI-973 correlates with cellular platinum levels in rat renal cortical slices.
Leibbrandt ME; Wolfgang GH
Toxicol Appl Pharmacol; 1995 Jun; 132(2):245-52. PubMed ID: 7785052
[TBL] [Abstract][Full Text] [Related]
60. The in vitro renal cell toxicity of some unconventional anticancer phenanthroline-based platinum(II) complexes.
Ng NS; Wu MJ; Myers SJ; Aldrich-Wright JR
J Inorg Biochem; 2018 Feb; 179():97-106. PubMed ID: 29197671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
